TISSUE CROSS-REACTIVITY STUDY OF A HUMAN ANTIBODY

NIH RePORTER · NIH · N02 · $107,538 · view on reporter.nih.gov ↗

Abstract

The test agent is being considered for development as an anticancer therapeutic. The objective of this task was to obtain a source of tissue or cells for in vitro evaluations of toxicity. The information obtained from this investigation was used to identify drugs with the potential to treat cancer.

Key facts

NIH application ID: 10474740
Project number: 261201600017I-0-759102100001-1
Recipient: SRI INTERNATIONAL
Principal Investigator: JON MIRSALIS
Activity code: N02
Funding institute: NIH
Fiscal year: 2021
Award amount: $107,538
Award type: —
Project period: 2021-04-09 → 2022-04-08